Proteostasis Therapeutics, Inc. (PTI) SEC Filing 8-K Material Event for the period ending Monday, October 22, 2018

Proteostasis Therapeutics, Inc.

CIK: 1445283 Ticker: PTI

View differences made from one to another to evaluate Proteostasis Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Proteostasis Therapeutics, Inc..


Assess how Proteostasis Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Proteostasis Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Proteostasis Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PTI
CIK: 1445283
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-306412
Submitted to the SEC: Wed Oct 24 2018 4:28:40 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Monday, October 22, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: